In vitro selective inhibition of human UDP-glucuronosyltransferase (UGT) 1A4 by finasteride, and prediction of in vivo drug–drug interactions
- 1 January 2015
- journal article
- Published by Elsevier in Toxicology Letters
- Vol. 232 (2) , 458-465
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Science, ICT & Future Planning (2013M3A9B5075838)
This publication has 44 references indexed in Scilit:
- Comparison of the Drug-Drug Interactions Potential of Erlotinib and Gefitinib via Inhibition of UDP-GlucuronosyltransferasesDrug Metabolism and Disposition, 2010
- Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with ZidovudineDrug Metabolism and Disposition, 2009
- DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOSDrug Metabolism and Disposition, 2004
- Development of an Assay Using 4-Trifluoromethylumbelliferyl as a Marker Substrate for Assessment of Drug–Drug Interactions to Multiple Isoforms of UDP-GlucuronosyltransferasesASSAY and Drug Development Technologies, 2004
- Database analyses for the prediction of in vivo drug–drug interactions from in vitro dataBritish Journal of Clinical Pharmacology, 2004
- Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 InhibitionClinical Pharmacokinetics, 2000
- Clinical Pharmacokinetics and Pharmacodynamics of FinasterideClinical Pharmacokinetics, 1996
- Finasteride, A Steroid 5α‐Reductase Inhibitor, Does Not Affect the Oxidative Metabolism of AntipyrineThe Journal of Clinical Pharmacology, 1993
- FinasterideDrugs, 1993
- Finasteride: A slow-binding 5.alpha.-reductase inhibitorBiochemistry, 1993